Spots Global Cancer Trial Database for Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

Official Title: A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases

Study ID: NCT01444807

Conditions

Metastatic Renal Cell Carcinoma

Interventions

sorafenib

Study Description

Brief Summary: Evaluate the efficacy and tolerability of sorafenib in RCC patients underwent to metastasectomy

Detailed Description: Advanced RCC presents poor prognosis, because its pathogenesis is not clearly understood. However, up-regulation of the Ras pathway is thought to play a role. VEGF expression could represent independent prognostic factors for survival possibly linking expression of this protein with clinical outcome. Sorafenib is a potent inhibitor of both Raf-kinase and VEGF R2 signalling The anti-tumoral activity of Sorafenib was clearly demonstrated in phase III trial regarding advanced pretreated RCC. Surgical removal of metastatic disease could potentially increase the disease control rate. Particularly in patients with a disease free interval post nephrectomy of at least 1 year, with one small metastatic lesion, metastasectomy could represents an important therapeutic approach. After a radical resection of the metastatic disease is unclear if an anti-tumoral systemic therapy may increase patient survival. In summary, both the preclinical and clinical data support further evaluation of Sorafenib in RCC patients.